This company listing is no longer active
CFRX Stock Overview
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ContraFect Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.069 |
| 52 Week High | US$13.02 |
| 52 Week Low | US$0.043 |
| Beta | 0.65 |
| 1 Month Change | -72.99% |
| 3 Month Change | -91.08% |
| 1 Year Change | -99.39% |
| 3 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Contrafect GAAP EPS of -$0.46 misses by $0.13
Aug 15ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial
Jul 13ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans
Jun 29
Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Dec 25ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
Sep 15We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
Aug 18Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?
May 01Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Mar 09Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Jan 15What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?
Nov 24Contrafect EPS beats by $0.16
Nov 13Shareholder Returns
| CFRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.2% | -2.0% | -2.5% |
| 1Y | -99.4% | -8.7% | 21.6% |
Return vs Industry: CFRX underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: CFRX underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| CFRX volatility | |
|---|---|
| CFRX Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CFRX's share price has been volatile over the past 3 months.
Volatility Over Time: CFRX's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | Mike Messinger | www.contrafect.com |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
ContraFect Corporation Fundamentals Summary
| CFRX fundamental statistics | |
|---|---|
| Market cap | US$676.12k |
| Earnings (TTM) | -US$24.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CFRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CFRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.14m |
| Earnings | -US$24.14m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CFRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/04 11:23 |
| End of Day Share Price | 2023/12/04 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ContraFect Corporation is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |
| Esther Lannie Hong | Janney Montgomery Scott LLC |